Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Pathologic Processes × MRX-2843 × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pathologic Processes 1 Neoplastic Processes 1 Neoplasms 1 Neoplasm Metastasis 1 Leukemia, Myeloid, Acute 1 Leukemia, Biphenotypic, Acute 1

Interventions

pembrolizumab 1 Pemetrexed 1 MRX-2843 1 Control Groups 1 Cisplatin 1 Carboplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03510104 2026-01-08

Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors

Meryx, Inc.

Phase 1 Completed

Neoplasm Metastasis, Neoplasms, Neoplastic Processes, Pathologic Processes

Data powered by HemOnc (CC BY 4.0) Colophon ⚡